Get the Stockscreener App
21.37
0.05%
-0.010
After Hours:
21.37
Day One Biopharmaceuticals Inc stock is traded at $21.37, with a volume of 1.81M.
It is down -0.05% in the last 24 hours and up +95.52% over the past month.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY301 is an antibody drug conjugate (ADC) that has shown antitumor activity in preclinical models.
See More
Previous Close:
$21.38
Open:
$21.38
24h Volume:
1.81M
Relative Volume:
0.43
Market Cap:
$2.21B
Revenue:
$158.18M
Net Income/Loss:
$-107.32M
P/E Ratio:
-20.51
EPS:
-1.0421
Net Cash Flow:
$-107.58M
1W Performance:
+0.28%
1M Performance:
+95.52%
6M Performance:
+219.91%
1Y Performance:
+158.09%
1-Day Range:
$21.36
$21.41
1-Week Range:
$21.29
$21.44
52-Week Range:
$5.635
$21.44
Day One Biopharmaceuticals Inc Stock (DAWN) Company Profile
Name
Day One Biopharmaceuticals Inc
Sector
Industry
Phone
650 484-0899
Address
1800 SIERRA POINT PARKWAY, SUITE 200, BRISBANE
Compare DAWN vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DAWN
Day One Biopharmaceuticals Inc
|
21.37 | 2.21B | 158.18M | -107.32M | -107.58M | -1.0421 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Day One Biopharmaceuticals Inc Stock (DAWN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-10-26 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jan-13-26 | Resumed | TD Cowen | Buy |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Oct-09-24 | Reiterated | Needham | Buy |
| Aug-01-24 | Upgrade | BofA Securities | Underperform → Buy |
| Apr-24-24 | Reiterated | Needham | Buy |
| Apr-25-23 | Downgrade | BofA Securities | Buy → Underperform |
| Feb-08-23 | Initiated | CapitalOne | Overweight |
| Feb-03-23 | Initiated | Oppenheimer | Perform |
| Dec-15-22 | Initiated | H.C. Wainwright | Buy |
| Dec-14-22 | Initiated | Needham | Buy |
| Dec-05-22 | Initiated | Goldman | Buy |
| Dec-01-22 | Initiated | BofA Securities | Buy |
View All
Day One Biopharmaceuticals Inc Stock (DAWN) Latest News
Servier (DAWN) plans tender offer under March 6, 2026 merger agreement - Stock Titan
Aug Breakouts: Will Day One Biopharmaceuticals Inc stock go up in YEAR2026 Intraday Action & High Conviction Buy Zone Alerts - baoquankhu1.vn
Day One Biopharmaceuticals stock hits 52-week high at $21.44 By Investing.com - Investing.com Australia
Day One Biopharmaceuticals (NASDAQ:DAWN) Reaches New 1-Year HighShould You Buy? - MarketBeat
Day One Biopharmaceuticals stock hits 52-week high at $21.44 - Investing.com
Glazer Capital (NASDAQ: DAWN) reports 5.6M-share, 5.44% stake - Stock Titan
Take Profit: Is Day One Biopharmaceuticals Inc a strong growth stockStock Surge & AI Driven Stock Reports - baoquankhu1.vn
Day One Biopharmaceuticals reiterates $225M–$250M OJEMDA revenue target as pipeline expands with Emi-Le integration - MSN
Trading Action: What are the future prospects of Day One Biopharmaceuticals IncRisk Management & AI Forecasted Stock Moves - baoquankhu1.vn
XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements - GlobeNewswire Inc.
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
(DAWN) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Mak Capital One LLC Invests $10.21 Million in Day One Biopharmaceuticals, Inc. $DAWN - MarketBeat
Algert Global LLC Buys 411,000 Shares of Day One Biopharmaceuticals, Inc. $DAWN - MarketBeat
MRSN Stock Soars Over 200% Pre-Market After Day One Acquisition Deal - MSN
DAWN stock jumps 66% on $2.5B buyout offer from Servier - MSN
Are DAWN, TALK, UNF Obtaining Fair Deals for their Shareholders? - Sahm
Servier All Cash Deal Reframes Day One Biopharmaceuticals Valuation Story - Sahm
Servier Acquires Day One Biopharmaceuticals for $2.5B, Betting on Tovorafenib and the Pediatric Glioma Frontier - Oncodaily
symbol__ Stock Quote Price and Forecast - CNN
HC Wainwright & Co. downgrades Day One Biopharmaceuticals (DAWN) - MSN
Are DAWN, TALK, UNF Obtaining Fair Deals for their Shareholders? – Company Announcement - Financial Times
The M&A Class Action Firm Encourages $hareholders to Contact Monteverde Concerning the Merger—DAWN, SEM, FONR, and EWCZ - Carroll County Mirror-Democrat
Day One Biopharmaceuticals gains amid takeover speculation - MSN
A Look At Day One Biopharmaceuticals (DAWN) Valuation After Recent Share Price Momentum - Yahoo Finance
EDGAR Filing Documents for 0001193125-24-108544 - SEC.gov
This VICI Properties Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Wednesday - Benzinga
Day One Biopharmaceuticals (NASDAQ:DAWN) Given "Neutral" Rating at JPMorgan Chase & Co. - MarketBeat
JPMorgan downgrades Day One Biopharmaceuticals stock rating on Servier acquisition - Investing.com Canada
Servier to acquire Day One Biopharmaceuticals for $2.5 billion - Investing.com Nigeria
Day One Biopharmaceuticals Acquires Mersana Therapeutics: Key Financial Details, Purchase Price, and Pro Forma Impact - Minichart
This Day One Biopharmaceuticals Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday - Benzinga
Day One Biopharmaceuticals' (DAWN) "Neutral" Rating Reiterated at HC Wainwright - MarketBeat
Day One Biopharma : DAWN - 24/7 Wall St.
Day One Biopharmaceutical (DAWN) Downgraded to Neutral by HC Wai - GuruFocus
Day One (DAWN) soars 100% on $2.5-billion merger - MSN
Are DAWN and TALK Obtaining Fair Deals for their Shareholders? - Finviz
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Day One Biopharmaceuticals, Inc. Buyout: Why Servier’s $2.5 Billion Ojemda Deal Matters Now - TechStock²
Day One (DAWN) climbs to 3-year high on $2.5-billion merger - MSN
DAWN Stock Jumps 66% on $2.5B Buyout Offer From Servier - The Globe and Mail
DAWN Stock Downgraded by Wedbush with Price Target Adjustment | - GuruFocus
Wedbush Reaffirms Neutral Rating for Day One Biopharmaceuticals (NASDAQ:DAWN) - MarketBeat
Day One Biopharmaceuticals Touts OJEMDA Sales Surge, Sets $225M-$250M 2026 Outlook at TD Cowen - MarketBeat
Servier acquires International Biotech's Day One for USD2.5 billion - marketscreener.com
Day One Biopharma Earnings Call Highlights Ojemda Surge - The Globe and Mail
Day One (DAWN) Soars 100% on $2.5-Billion Merger - Yahoo Finance
Top Small Cap Stocks To Add to Your WatchlistMarch 7th - MarketBeat
Key deals this week: Diana Shipping, Day One Biopharmaceuticals, Hudbay Minerals and more - Seeking Alpha
Pharmaceutical Stocks To ResearchMarch 7th - MarketBeat
JonesTrading Maintains Buy Rating on Day One Biopharmaceuticals (DAWN) Following Ojemda’s FDA Approval - MSN
Day One Biopharmaceuticals Inc Stock (DAWN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):